Close Menu

NEW YORK – PierianDx will integrate the Pillar Biosciences PiVAT cancer bioinformatics pipeline into its core technology platform, the companies announced Wednesday. Under the new partnership, Pillar Bio, which has co-headquarters in Boston and Shanghai, will market PieranDx clinical genomic reports along with its own cancer profiling assays.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.